Abstract
DRG neurones are a heterogeneous population of neurones that vary in sensory transduction mechanisms, myelination, axon diameter, cell soma size, neurotransmitter content, receptor and ion channel expression. The generation, conduction, integration and transmission of pain signals begin in DRG neurones and they remain an important target for therapeutic intervention in pain disorders. In this review we discuss the expression of cannabinoid receptors in DRG neurones. We will also discuss the actions and molecular mechanisms of cannabinoid receptor ligands in the context of modulating sensory neurone excitability. Evidence suggests that vanilloid and cytokine receptor functions, voltageactivated Ca2+ and K + channels and Ca2+-activated channels are all either direct or indirect sites that might be modulated by synthetic and endogenous cannabinoid ligands.
Keywords: Neurones, heterogeneous, myelination
Current Neuropharmacology
Title: Cannabinoids and Sensory Neurones
Volume: 2 Issue: 1
Author(s): Ruth A. Ross, Rhian M. Evans and Roderick H. Scott
Affiliation:
Keywords: Neurones, heterogeneous, myelination
Abstract: DRG neurones are a heterogeneous population of neurones that vary in sensory transduction mechanisms, myelination, axon diameter, cell soma size, neurotransmitter content, receptor and ion channel expression. The generation, conduction, integration and transmission of pain signals begin in DRG neurones and they remain an important target for therapeutic intervention in pain disorders. In this review we discuss the expression of cannabinoid receptors in DRG neurones. We will also discuss the actions and molecular mechanisms of cannabinoid receptor ligands in the context of modulating sensory neurone excitability. Evidence suggests that vanilloid and cytokine receptor functions, voltageactivated Ca2+ and K + channels and Ca2+-activated channels are all either direct or indirect sites that might be modulated by synthetic and endogenous cannabinoid ligands.
Export Options
About this article
Cite this article as:
Ross A. Ruth, Evans M. Rhian and Scott H. Roderick, Cannabinoids and Sensory Neurones, Current Neuropharmacology 2004; 2 (1) . https://dx.doi.org/10.2174/1570159043476882
DOI https://dx.doi.org/10.2174/1570159043476882 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Novel Agents Targeting Crucial Signalling Pathways in Head and Neck Squamous Cell Carcinoma, HNSCC - Preclinical Development and Data from Clinical Trials
Current Proteomics A Transporter Gene (Sodium Iodide Symporter) for Dual Purposes in Gene Therapy: Imaging and Therapy
Current Gene Therapy Neuroprotection & Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects for an Ancient Drug
Current Drug Targets Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment
Current Medicinal Chemistry Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Current Drug Targets Anti-MDR Effects of Quercetin and its Nanoemulsion in Multidrug-Resistant Human Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Clinical Studies with Targeted Toxins in Malignant Glioma
Reviews on Recent Clinical Trials The Proteolytic Activation of Angiogenic and Lymphangiogenic Growth Factors in Cancer – Its Potential Relevance for Therapeutics and Diagnostics
Current Medicinal Chemistry Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
Current Medicinal Chemistry Epigenetics in Clinical Management of Children and Adolescents with Brain Tumors
Current Cancer Drug Targets Lymphocytes in Alzheimer’s Disease Pathology: Altered Signaling Pathways
Current Alzheimer Research Advanced Micro-Nano-Bio Systems for Future Targeted Therapies
Current Nanoscience Procyanidin B2 3,3″-di-O-gallate Inhibits Endothelial Cells Growth and Motility by Targeting VEGFR2 and Integrin Signaling Pathways
Current Cancer Drug Targets Heme Oxygenase-1 in Tumor Biology and Therapy
Current Drug Targets Radiolabelled Molecules for Imaging the Translocator Protein (18 kDa) Using Positron Emission Tomography
Current Medicinal Chemistry Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions
Current Signal Transduction Therapy PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence
Current Drug Targets Mesenchymal Stem Cells in the Umbilical Cord: Phenotypic Characterization, Secretome and Applications in Central Nervous System Regenerative Medicine
Current Stem Cell Research & Therapy